<DOC>
	<DOCNO>NCT01381419</DOCNO>
	<brief_summary>This study describe present protocol consist two section . Part A first administration man evaluate safety , tolerability pharmacokinetics single ascend dos GSK1144814 . The study single-blind , randomise , placebo-controlled design healthy male female ( non-childbearing potential ) subject . Part B open-label design healthy male subject assess GSK1144814 neurokinin-1 ( NK1 ) receptor occupancy positron emission tomography ( PET ) scan [ 11C ] -GR205171</brief_summary>
	<brief_title>First Time Human Study ( FTIH ) With Positron Emission Tomography ( PET )</brief_title>
	<detailed_description>GSK1144814 dual neurokinin-1 ( NK1 ) neurokinin-3 ( NK3 ) antagonist potential treat schizophrenia &amp; depression . This study describe present protocol consist two section . Part A first administration man evaluate safety , tolerability pharmacokinetics single ascend dos GSK1144814 . The study single-blind , randomise , placebo-controlled design healthy male female ( non-childbearing potential ) subject . Part B open-label design healthy male subject assess GSK1144814 NK1 receptor occupancy positron emission tomography ( PET ) scan [ 11C ] -GR205171 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include , opinion Investigator , find unlikely introduce additional risk factor interfere study procedure . Male female age 18 55 year ( inclusive ) Part A , male age 25 55 year ( inclusive ) Part B . A female subject eligible participate Part A : • Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] &gt; 40 mIU/mL oestradiol &lt; 40 pg/mL [ &lt; 140 pmol/L ] confirmatory ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require discontinue HRT allow confirmation postmenopausal status prior study enrolment . For form HRT , least 2 4 week elapse cessation therapy blood sampling ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . A male subject must agree use one contraception method list Section 8.1 . This criterion must follow first investigational product dose day least 3 month receive last dose investigational product . Body weight ≥50 kg body mass index ( BMI ) within range 18 29.9 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec . Demonstrates evidence mental impairment comorbid psychiatric disorder . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy hepatitis B surface antigen ( HBsAg ) positive hepatitis C virus ( HCV ) antibody test result within 3 month Screening . A positive test result antibody human immunodeficiency virus ( HIV ) 1/2 . Significant renal abnormality ( medical history indicate laboratory investigation . In addition , subject idiopathic haematuria proteinuria condition benign orthostatic proteinuria benign familial haematuria exclude study ) . History regular alcohol consumption within 6 month study start define : • An average weekly intake great 21 unit average daily intake great 3 unit ( male ) , defined average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent halfpint ( 220 mL ) beer 1 measure ( 25 mL ) spirit 1 glass ( 125 mL ) wine . The subject participate clinical trial receive investigational product within 3 month prior first investigational product dose day current study . Exposure four new chemical entity within 12 month prior first investigational product dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior receive first dose investigational product , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity investigational product , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation study . Where participation study would result donation blood blood product excess 500 mL within 56day period . Unwillingness inability follow procedure outline protocol . History presence clinically significant cardiac arrhythmia , clinically significant cardiac disease . Smokers confirm positive urinary cotinine test ( great local laboratory lower limit quantification [ LLQ ] 200 ng/mL low ) . Urine cotinine level measure Screening Baseline . Consumption Seville orange ( include marmalade ) and/or grapefruit and/or Chinese grapefruit ( pomelo ) and/or grapefruit hybrid and/or exotic citrus fruit and/or fruit juice 7 day prior first investigational product dose day . Consumption red wine 7 day prior first investigational product dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>positron emission tomography ( PET )</keyword>
	<keyword>single ascend dose</keyword>
</DOC>